Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients

Cytokine

Volumn 47, Issue 1, 2009, Pages 1-5

  Singh, Bisu ^a   Bera, Nirmal Kumar ^b   Nayak, Chitta R ^a   Chaudhuri, Tapas Kumar ^a  

^a UNIVERSITY OF NORTH BENGAL   (India)

^b NORTH BENGAL MEDICAL COLLEGE   (India)

Author keywords

Interleukin 2; Interleukin 6; Psychotropic; Schizophrenia

Indexed keywords

CLOZAPINE; INTERLEUKIN 2; INTERLEUKIN 6; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGE; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; INDIAN; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; INDIA; INTERLEUKIN-2; INTERLEUKIN-6; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIA, PARANOID; YOUNG ADULT;

EID: 67449103836     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.05.005     Document Type: Article

References (57)

1. Male D., Cooke A., Owen M., Trowsdale J., and Champion B. Cytokines and chemokines. Advanced immunology. 3rd ed. (1996), Mosby, London
2. Muller N., and Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 22 (1998) 1-33
3. Kronfol Z., and Remick D.G. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 157 (2000) 683-694
4. Muller N., Riedel M., Ackenheil M., and Schwarz M.J. The role of immune function in schizophrenia: an overview. Eur Arch Psychiatry Clin Neurosci 249 Suppl. 4 (1999) 62-68
5. Ganguli R., Rabin B.S., and Belle S.H. Decreased IL-2 production in schizophrenic patients. Biol Psychiatry 26 (1989) 427-430
6. Ganguli R., Brar J.S., Chengappa K.N.R., Deleo M., Yang Z.W., Shurin G., et al. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. Arch Gen Psychiatry 52 (1995) 668-672
7. Villemain F., Chatenoud L., Galinowski A., Homo-Delarche F., Ginestet D., Loo H., et al. Aberrant T cell-immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am J Psychiatry 146 (1989) 609-616
8. Bessler H., Levental Z., Karp L., Mondai I., Djaldetti M., and Weizman A. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry 38 (1995) 297-302
9. Arolt A., Rothermund M., Wandinger K.P., and Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 5 (2000) 150-158
10. Kim Y.K., Kim L., and Lee M.S. Relationship between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 44 (2000) 165-175
11. Maes M., Bosmans E., Calabree J., Smith R., and Meltzer H. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29 (1995) 141-152
12. Frommberger U.H., Bauer J., Haselbauer P., Fraulin A., Riemann D., and Berger M. Interleukin-6 plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 247 (1997) 228-233
13. Lin A., Kenis G., Bignotti S., Tura G.J., De Jong R., Bosmans E., et al. The inflammatory response system in treatment-resistant and schizophrenia: increase serum interleukin-6. Schizophr Res 32 (1998) 9-15
14. Muller N., Dobmeier P., Empel M., Riedel M., Schwarz M., and Ackenheil M. Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients. Eur Psychiatry 12 (1997) 294-299
15. Van Kammen D.P., Mc Allister-Sistilli C.G., Kelley M.E., Gurklis J.A., and Yao J.K. Elevated interleukin-6 in schizophrenia. Psychiatry Res 87 (1999) 129-136
16. Na K.S., and Kim Y.K. Monocytic, Th1 and Th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology 56 (2007) 55-63
17. Cazzullo C.L., Saresella M., Roda K., Calvo M.G., Bertrando P., Doria S., et al. Increase levels of CD8+ and CD4+ 45RA lymphocytes in schizophrenic patients. Schizophr Res 31 (1998) 49-55
18. Cazzullo C.L., Scarone S., Grassi B., Vismara C., Trabattoni D., and Clerici M. Cytokines production in chronic schizophrenia patients with or without paranoid behavior. Prog Neuropsychopharmacol Biol Psychiatry 22 (1998) 947-957
19. Mittleman B.B., Castellanos F.X., Jacobson L.K., Rapport J.L., Sewdo S.E., and Shearer G.M. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol 159 (1997) 2994-2999
20. Baker I., Masserano J., and Wyatt R.J. Serum cytokine concentrations in patients with schizophrenia. Schizophr Res 20 (1996) 199-203
21. Potvin S., Stip E., Sepehry A.A., Gendron A., and Bah R. Inflammatory cytokine alterations in schizophrenia: asystematic quantitative review. Biol Psychiatry 63 (2008) 801-808
22. Pollmacher T., Hinze-Selch D., and Mullingto J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 16 (1996) 403-409
23. Maes M., Bosmans E., Kenis G., et al. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 26 (1997) 221-225
24. Drzyzga L., Obuchowicz E., Marcinowska A., and Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 20 (2006) 532-545
25. Akiyama K. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr Res 37 (1999) 97-106
26. Pollmacher T., Hinze-Selch D., Fenzel T., et al. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am J Psychiatry 154 (1997) 1763-1765
27. Coelho F.M., Reis H.J., Nicolato R., Romano-Silva M.A., Teixeira M.M., Bauer M.E., et al. Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia. Neuroimmunomodulation 15 (2008) 140-144
28. Zalcman S., Green-Johnsom J.M., Murray L., Nance D.M., Dyck D., Anisman H., et al. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 643 (1994) 40-49
29. Denicoff K.D., Rubinow D.R., Papa M.Z., Simpson C., Seipp C.A., Lotze M.T., et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 107 (1987) 293-300
30. Kahn M.A., and De Vellis J. Regulation of an oligodendrocyte progenitor cell line by the interleukin-6 family of cytokines. Glia 12 (1994) 87-98
31. Qiu Z., Sweeney D.D., Netzeband J.G., and Gruol D.L. Chronic interleukin-6 alters NMDA receptor mediated membrane responses and enhances neurotoxicity in developing CNS neurons. J Neurosci 18 (1998) 10445-10456
32. Graver D.L., Tamas R.L., and Holcomb J.A. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology 28 (2003) 1515-1520
33. TM. American Psychiatric Association. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd.; 2002.
34. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV axis I disorders, patient edition (SCID-P), version 2. New York: Biometrics Research; 1996.
35. Overall J.E., and Gorham D.R. The brief psychiatric rating scale. Arch Gen Psychiatry 16 (1962) 146-151
36. Theodoropoulou S., Spanokos G., Baxevanis C.N., Economou M., Gritzapis A.D., Papamichail M.P., et al. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res 47 (2001) 13-25
37. Ebrinc S., Top C., Oncul O., Basoglu C., Cavuslu S., and Cetin M. Serum interleukin 1α and Interleukin-2 levels in patients with schizophrenia. J Int Med Res 30 (2002) 314-317
38. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Cao L.Y., and Shen Y.C. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 57 (2002) 247-258
39. Zhang X.Y., Zhou D.F., Cao Y.L., Wu G.Y., and Shen Y.C. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 30 (2005) 1532-1538
40. Kim Y.K., Lee M.S., and Suh K.Y. Decreased interleukin-2 production in Korean schizophrenic patients. Biol Psychiatry 43 (1998) 701-704
41. Pulver A. Search for schizophrenia susceptibility genes. Biol Psychiatry 47 (2000) 221-230
42. Kirkpatrick B., Buchanan R.W., Ross D.E., and Carpenter W.T. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 58 (2001) 165-171
43. Garver D.L., Kelly K., Fried K.A., Magnusson M., and Hirschowitz J. Drug response patterns as a basis of nosology for the mood-incongruent psychoses. Psychol Med 18 (1988) 873-886
44. Garver D.L., Nair T.R., Christensen J.D., Holcomb J., Ramberg J., and Kingsbury S. Atrophic and static (neurodevelopmental) schizophrenic psychoses: premorbid functioning, symptoms and neuroleptic response. Neuropsychopharmacology 21 (1999) 82-92
45. Garver D.L., Holcomb J.A., and Christensen J.D. Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. J Clin Psychiatry 61 (2000) 964-972
46. Hoffmann S.C., Stanley E.M., Cox E.D., Di Mercurio B.S., Koziol D.E., Harlan D.M., et al. Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant 2 (2002) 560-567
47. Maes M., Bosmans E., Calabrese J., Smith R., and Meltzer H. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29 (1995) 141-152
48. Song C., Lin A.H., Kenis G., Bosmans E., and Maes M. Immuno-suppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr Res 42 (2000) 157-164
49. Leykin I., Mayer R., and Schinitzky M. Short and long term immunosuppressive effects of clozapine an haloperidol. Immunopharmacology 37 (1997) 75-86
50. Maes M., Chiavetto L.B., Bignotti S., Tura G.J.B., Pioli R., Boin F., et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 10 (2000) 119-124
51. Schuld A., Hinze-Selch D., and Pollmacher T. Cytokine network in patients with schizophrenia and its significance for the pathophysiology of the illness. Nervenarzt 75 (2004) 215-226
52. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., and Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities an secreted proteins. J Immunol 136 (1986) 2348-2357
53. Romagnani S. Biology of human TH1 and TH2 cells. J Clin Immunol 15 (1995) 121-129
54. Lucy D.R., Clerici M., and Shearer G.M. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 9 (1996) 532-562
55. Schwarz M.J., Chiang S., Muller N., and Ackenheil M. T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav Immun 15 (2001) 340-370
56. Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol 6 (2006) 329-333
57. Tato C.M., Laurence A., O'Shea J.J., and Helper T. Cell differentiation enters a new era: Le roi est mort; vive le roi!. J Exp Med 203 (2006) 809-812